论文部分内容阅读
目的:观察清肺汤治疗小儿支原体肺炎(MP)的临床疗效及其对血清炎性细胞因子水平的影响。方法:84例MP患儿,随机分为常规治疗组35例和中药组49例。2组患儿均给予止咳化痰、解热等对症处理。常规治疗组给予阿奇霉素治疗;中药组在此基础上给予清肺汤治疗。连服1周。观察并比较记录患者发热、咳嗽及肺部啰音消失时间检测治疗前后血清超敏C-反应蛋白(hs-CRP)及白细胞介素-2(IL-2)和白细胞介素-6(IL-6)水平的变化。结果:总有效率中药组98.0%,常规治疗组82.9%,2组比较,差异有统计学意义(P<0.05)。中药组发热、咳嗽及肺部啰音消失时间均明显短于常规治疗组,2组比较,差异有统计学意义(P<0.05)。2组治疗后hs-CRP和IL-6水平显著下降,IL-2显著升高,与本组治疗前比较,差异有统计学意义(P<0.01);但中药组hs-CRP和IL-6水平下降程度更为明显,与常规治疗组比较,差异有统计学意义(P<0.01),中药组IL-2水平升高程度更为明显,与常规治疗组比较,差异有统计学意义(P<0.01)。结论:清肺汤治疗小儿支原体肺炎临床疗效肯定,其机制可能通过降低IL-2水平,升高IL-6水平来调节炎性细胞水平发挥抗炎治疗作用的。
Objective: To observe the Qingfei Decoction treatment of children with mycoplasma pneumonia (MP) and its clinical effect on serum levels of inflammatory cytokines. Methods: Eighty-four cases of MP children were randomly divided into routine treatment group (35 cases) and traditional Chinese medicine group (49 cases). Two groups of children were given symptomatic treatment of cough and phlegm, antipyretic. Conventional treatment group given azithromycin treatment; Chinese medicine group on the basis of Qingfei Tang treatment. Even for 1 week. The levels of serum hs-CRP, IL-2 and IL-6 in patients with fever, cough and pulmonary rales disappeared were observed before and after treatment. 6) The level of change. Results: The total effective rate was 98.0% in traditional Chinese medicine group and 82.9% in conventional treatment group. There was significant difference between the two groups (P <0.05). Chinese medicine group fever, cough and pulmonary rales disappeared significantly shorter than the conventional treatment group, the two groups, the difference was statistically significant (P <0.05). The levels of hs-CRP and IL-6 in the two groups were significantly decreased (P <0.01), while the levels of IL-2 and IL-6 in the two groups were significantly decreased (P <0.01). The level of IL-2 in the Chinese medicine group was more obvious than that in the conventional treatment group (P <0.01), and the difference was statistically significant (P <0.01). Conclusion: Qingfei decoction is effective in treating children with mycoplasmal pneumonia. Its mechanism may play an anti-inflammatory therapeutic effect by decreasing the level of IL-2 and increasing the level of IL-6 in inflammatory cells.